company background image
A241

PCL KOSDAQ:A241820 Stock Report

Last Price

₩25.70k

Market Cap

₩278.8b

7D

-7.4%

1Y

-47.0%

Updated

24 May, 2022

Data

Company Financials
A241820 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

A241820 Stock Overview

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services.

PCL Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for PCL
Historical stock prices
Current Share Price₩25,700.00
52 Week High₩64,500.00
52 Week Low₩24,200.00
Beta-1.22
1 Month Change-13.03%
3 Month Change-47.76%
1 Year Change-47.01%
3 Year Change171.10%
5 Year Change307.94%
Change since IPO180.57%

Recent News & Updates

Shareholder Returns

A241820KR Medical EquipmentKR Market
7D-7.4%0.8%1.2%
1Y-47.0%-4.7%-14.3%

Return vs Industry: A241820 underperformed the KR Medical Equipment industry which returned -4.7% over the past year.

Return vs Market: A241820 underperformed the KR Market which returned -14.3% over the past year.

Price Volatility

Is A241820's price volatile compared to industry and market?
A241820 volatility
A241820 Average Weekly Movement10.0%
Medical Equipment Industry Average Movement5.6%
Market Average Movement5.4%
10% most volatile stocks in KR Market10.2%
10% least volatile stocks in KR Market3.1%

Stable Share Price: A241820 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: A241820's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aSo-Youn Kimhttps://www.pclchip.com

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control.

PCL Fundamentals Summary

How do PCL's earnings and revenue compare to its market cap?
A241820 fundamental statistics
Market Cap₩278.77b
Earnings (TTM)-₩27.33b
Revenue (TTM)₩42.99b

6.3x

P/S Ratio

-9.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A241820 income statement (TTM)
Revenue₩42.99b
Cost of Revenue₩38.89b
Gross Profit₩4.09b
Other Expenses₩31.42b
Earnings-₩27.33b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.61k
Gross Margin9.52%
Net Profit Margin-63.58%
Debt/Equity Ratio425.2%

How did A241820 perform over the long term?

See historical performance and comparison

Valuation

Is PCL undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


19.68x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A241820's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A241820's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: A241820 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the KR Medical Equipment industry average.

PE vs Market: A241820 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the KR market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A241820's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A241820 is overvalued based on its Price-To-Book Ratio (19.7x) compared to the KR Medical Equipment industry average (2.4x).


Future Growth

How is PCL forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


4.7%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PCL has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has PCL performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-5.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A241820 is currently unprofitable.

Growing Profit Margin: A241820 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: A241820 is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.

Accelerating Growth: Unable to compare A241820's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A241820 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.1%).


Return on Equity

High ROE: A241820 has a negative Return on Equity (-199.03%), as it is currently unprofitable.


Financial Health

How is PCL's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A241820's short term assets (₩93.0B) exceed its short term liabilities (₩91.0B).

Long Term Liabilities: A241820's short term assets (₩93.0B) exceed its long term liabilities (₩4.8B).


Debt to Equity History and Analysis

Debt Level: A241820's net debt to equity ratio (86.5%) is considered high.

Reducing Debt: A241820's debt to equity ratio has increased from 11.9% to 425.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A241820 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: A241820 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 38.8% each year.


Dividend

What is PCL current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A241820's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A241820's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A241820's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A241820's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A241820 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

So-Youn Kim (50 yo)

no data

Tenure

Ms. Kim serves as Chief Executive Officer at PCL Inc.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.


Top Shareholders

Company Information

PCL, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: PCL, Inc.
  • Ticker: A241820
  • Exchange: KOSDAQ
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: ₩278.772b
  • Shares outstanding: 10.48m
  • Website: https://www.pclchip.com

Location

  • PCL, Inc.
  • Star valley, 99
  • Room No. 701
  • Seoul
  • 8510
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.